Epidemiological features for primary lymphoma of the female genital tract patients and development of a nomogram to predict survival

Peng, Fei; Li, Jingwen; Mu, Shidai; Qin, You; Ma, Jinghong; Ai, Lisha; Hu, Yu

doi:10.1080/07853890.2022.2046289

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary uterine DLBCL is an extremely rare and poorly reported disease that normally occurs in postmenopausal women ( 6 ). Its cause, like most extra-nodal lymphomas, is unknown.…”

Section: Discussionmentioning

confidence: 99%

Primary diffuse large B-cell tumor of the uterus: a case report

Zhang

Yang

2023

Front. Med.

View full text Add to dashboard Cite

Primary diffuse large B-cell tumor of the uterus is a rare clinical condition with a similar clinical presentation to gynecologic tumors and is easily misdiagnosed. We report a case of a postmenopausal woman who presented with pelvic mass. Her ultrasound and MRI examinations suggested diffuse enlargement of the uterus, leading us to consider the diagnosis of lymphoma. The histological examination of the uterine mass confirmed the diagnosis of diffuse large B-cell lymphoma. The patient received 6 cycles of chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and 2 cycles of consolidation therapy with R (rituximab). After treatment, the patient's uterus was significantly smaller than before and there was no sign of a recurrence.

show abstract

“…Primary uterine DLBCL is an extremely rare and poorly reported disease that normally occurs in postmenopausal women ( 6 ). Its cause, like most extra-nodal lymphomas, is unknown.…”

Section: Discussionmentioning

confidence: 99%

Primary diffuse large B-cell tumor of the uterus: a case report

Zhang

Yang

2023

Front. Med.

View full text Add to dashboard Cite

show abstract

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group

Verrou,

Papageorgiou,

Bouzani

et al. 2024

Hematological Oncology

View full text Add to dashboard Cite

Involvement of female genital track (FGT) by diffuse large B cell lymphoma (DLBCL) represents an extremely rare diagnosis. Especially data regarding early‐stage disease (i.e., IE, IIE) is very limited. Importantly, previous studies showed controversial results about the risk of central nervous system (CNS) relapse in this entity. Herein, we describe one of the largest reported real‐world series of patients with early‐stage FGT DLBCL aiming to investigate the clinicopathological characteristics, response to therapy and survival outcomes in the era of immunochemotherapy. We analyzed 21 consecutive patients with biopsy proven DLBCL from uterus or ovary classified as stage IE or IIE out of 1905 newly diagnosed DLBCL patients (1.1%). Uterine and ovarian localization was observed in 14 and seven patients, respectively. Median age was 66 years (range 33–96); 9/21 (43%) were <55 years. Regarding Cell of Origin DLBCL subtype, Germinal Center B‐cell subtype was found in seven patients, non‐GCB in 10 and non‐classified in 4 patients. Median follow‐up was 57 months and 5‐year overall survival, lymphoma specific survival and Freedom from Progression were 78%, 89% and 90%, respectively. There was no correlation of patients' characteristics with survival parameters. Interestingly, none of the patients experienced CNS relapse. Our results indicate that localized FGT DLBCL exhibits a good prognosis and may not increase the risk for secondary CNS involvement.

show abstract

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Pirosa,

Steffanoni,

Vanazzi

et al. 2024

Hematological Oncology

View full text Add to dashboard Cite

Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (n = 24). The most common histological subtype was diffuse large B‐cell lymphoma (DLBCL, n = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first‐line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow‐up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5‐year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause‐specific, and progression‐free survival in patients with DLBCL.

show abstract

Epidemiological features for primary lymphoma of the female genital tract patients and development of a nomogram to predict survival

Cited by 4 publications

References 35 publications

Primary diffuse large B-cell tumor of the uterus: a case report

Primary diffuse large B-cell tumor of the uterus: a case report

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Contact Info

Product

Resources

About